Business Context and Reporting Period
Company: Novelos Therapeutics, Inc. (Note: Request metadata listed "Cellectar Biosciences," but the filing text identifies the registrant as Novelos Therapeutics, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: A biopharmaceutical company developing oxidized glutathione-based compounds for cancer (NOV-002) and hepatitis (NOV-205). The company is a smaller reporting company with no commercial revenue from product sales.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Revenue | $96,314 | $125,968 |
| Net Loss | $(22,273,306) | $(16,451,406) |
| Net Loss Attributable to Common Stockholders | $(26,283,626) | $(22,960,823) |
| Loss Per Share (Basic & Diluted) | $(0.53) | $(0.56) |
| Cash and Equivalents (Year End) | $8,769,529 | $1,262,452 |
| Derivative Liability | $10,486,594 | $0 |
| Accrued Dividends | $2,902,963 | $1,689,322 |
Note: The 2009 Net Loss includes a non-cash loss on derivative warrants of $12,114,371 due to the adoption of new accounting standards (FASB ASC 815-40).
Material Changes vs. Prior Period
- Revenue: Decreased by approximately 24% to $96,314, driven by a reduction in grant revenue from the U.S. Department of Health and Human Services ($63,000 in 2009 vs. $93,000 in 2008). License fee revenue remained flat at $33,000.
- Operating Expenses: Total costs and expenses decreased by 39% to $10.26 million. Research and Development (R&D) expenses dropped 44% to $8.08 million, primarily due to the conclusion of patient enrollment in the Phase 3 NSCLC trial and reduced clinical investigator costs.
- Derivative Liability: A new line item appeared in 2009. The company recorded a $12.1 million loss on derivative warrants, reflecting the fair value adjustment of warrants with "down-round" provisions reclassified from equity to liabilities.
- Liquidity: Cash and equivalents increased significantly from $1.26 million to $8.77 million, funded by $18.1 million in net proceeds from financing activities (issuance of Series E preferred stock and common stock).
Guidance, Outlook, Risks, and Unusual Items
Clinical Trial Results (Critical Event)
In February 2010, the company announced that its pivotal Phase 3 trial of NOV-002 in advanced non-small cell lung cancer (NSCLC) failed to meet its primary endpoint of improved overall survival. In March 2010, it was confirmed that secondary endpoints were also not met. Consequently, the company discontinued development of NOV-002 for NSCLC in combination with first-line paclitaxel and carboplatin.
Going Concern
The independent auditor has raised substantial doubt about the company's ability to continue as a going concern. Management believes cash is sufficient only through the fourth quarter of 2010. The company must secure additional capital to continue operations beyond that date.
Legal Proceedings
A class action lawsuit was filed on March 5, 2010, alleging violations of the Securities Exchange Act regarding disclosures related to the Phase 3 trial. The company intends to defend vigorously.
Outlook
Development continues for NOV-002 in breast cancer and ovarian cancer, and NOV-205 for chronic hepatitis C. However, the negative NSCLC results may adversely affect collaboration agreements with Mundipharma and Lee's Pharmaceutical.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to raise capital before the fourth quarter of 2010 to avoid ceasing operations.
- Derivative Liability: Confirm the impact of the $10.5 million derivative liability on future balance sheets and potential dilution upon warrant exercise.
- Preferred Stock Dividends: Note the $2.9 million in accrued unpaid dividends on Series C and E preferred stock, which may be paid in stock, causing further dilution.
- Collaboration Viability: Assess the risk that partners (Mundipharma, Lee's Pharm) may terminate or reduce payments due to the failed Phase 3 NSCLC trial.
- Legal Exposure: Monitor the status of the March 2010 class action lawsuit regarding Phase 3 trial disclosures.